SMA Capital’s Maze Therapeutics MAZE Stock Holding History

SMA Capital’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-134	Closed	-$4K	–	182
2026 Q1	$4K	Buy	+134	New	+$5.91K	﹤0.01%	93

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

SMA Capital's MAZE Position: Q2 2026 in Review

SMA Capital sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 134 shares — an estimated $4K sold.

SMA Capital first reported a position in MAZE in Q1 2026 and held it in 1 quarter. The position peaked at $4K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

SMA Capital reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 134 Maze Therapeutics shares in Q2 2026, an estimated $4K.
SMA Capital first reported a position in Maze Therapeutics in Q1 2026 and held it in 1 quarter.
SMA Capital's Maze Therapeutics position peaked at $4K in Q1 2026.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.